The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

The Ghana AIDS Commission (GAC) says the lack of funding can  impact negatively efforts to end AIDS as a public health threat ...

Like its English-language predecessor, which launched in 2016, this Spanish-language patient community from MyHealthTeam is ...